Qiagen stock gains 1.6 percent to EUR 40.84, market value EUR 8.4 billion

Published on 10/12/2026 at 13:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

BofA lifted its target from USD 49.00 to USD 50.00 on October 9, 2026. Qiagen stock stood at EUR 40.84 versus EUR 40.19 at Xetra.

Key points in brief

Qiagen stock was trading at EUR 40.84 at Lang & Schwarz on October 12, 2026, up 1.62 percent versus the Xetra close of EUR 40.19 on October 9, 2026.
Qiagen's market capitalization was EUR 8.4 billion and its P/E ratio was 23.3 as of October 12, 2026.
BofA raised its Qiagen price target from USD 49.00 to USD 50.00 on October 9, 2026, while the next earnings date was listed as November 4, 2026.
Second-quarter 2026 revenue reached USD 535.0 million and adjusted earnings per share reached USD 0.62, according to Simply Wall St.

Pipette tropft klare Flüssigkeit in sterile 96-Well-Platte, klinisches Laborlicht — Qiagen N.V. (NL0012169213) Pipette tropft klare Flüssigkeit in sterile 96-Well-Platte im klinischen Labor, Illustration mit AI erstellt.

Qiagen stock (ISIN NL0015002SN0) was trading at EUR 40.84 at Lang & Schwarz at 1:07 p.m. CEST on October 12, 2026, up 1.62 percent versus the Xetra close of October 9, 2026 at EUR 40.19. The move places the euro quotation below its 52-week high of EUR 47.60 and above its 52-week low of EUR 27.56.

Price position and trading range

The Lang & Schwarz quote carried a bid of EUR 40.81 and an ask of EUR 40.88 at 1:07 p.m. CEST. Qiagen's market capitalization was EUR 8.4 billion and its P/E ratio was 23.3 on October 12, 2026, giving the stock a valuation marker that can be compared directly with the current share price.

The stock stood 14.20 percent below its 52-week high, calculated from EUR 40.84 and EUR 47.60, while it was 48.07 percent above the 52-week low of EUR 27.56. This range leaves the current price materially closer to the yearly high than to the yearly low.

Analyst target moves higher

According to Markets Insider on October 9, 2026, BofA raised its Qiagen price target from USD 49.00 to USD 50.00 and kept a Buy rating. The target revision adds a dated U.S. dollar valuation reference, but it is not combined with the euro quotation.

For the second quarter of 2026, Qiagen reported revenue of USD 535.0 million and adjusted earnings per share of USD 0.62. Simply Wall St reported that revenue was flat year over year while adjusted earnings per share increased from USD 0.44 in the second quarter of 2025.

Comparison with peers

Qiagen: plus 1.62 percent, P/E 23.3, market capitalization EUR 8.4 billion

Thermo Fisher Scientific (NYSE, USD): plus 0.93 percent, P/E 35.4, market capitalization USD 243.3 billion

Bio-Rad Laboratories (NYSE, USD): plus 1.60 percent, P/E 44.4, market capitalization USD 9.9 billion

The peer figures are dated October 9, 2026. Qiagen's P/E was below the reported multiples for Thermo Fisher Scientific and Bio-Rad Laboratories, while its market value was far smaller than Thermo Fisher's and close to Bio-Rad's.

Next date on the calendar

Yahoo Finance listed November 4, 2026 as Qiagen's next earnings date. That event will provide the next dated test of the revenue and adjusted earnings trajectory reported for the second quarter.

On October 7, 2026, Qiagen announced expanded artificial intelligence capabilities for researchers, including new bioinformatics platforms, according to Simply Wall St. The announcement is separate from the market figures above and does not change the Xetra comparison base.

Qiagen stock price snapshot

At Lang & Schwarz, Qiagen stock was trading at EUR 40.84 on October 12, 2026 at 1:07 p.m. CEST, up 1.62 percent versus the Xetra close of October 9, 2026 at EUR 40.19. The quote was EUR 6.76 below the 52-week high of EUR 47.60.

The further course of trading is shown by the continuously updated real-time quote of Qiagen stock.